Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Recommendation of “Buy” by Analysts


Share on StockTwits

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been assigned a consensus rating of “Buy” from the twenty-two research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $174.59.

A number of analysts recently issued reports on JAZZ shares. Barclays raised their price objective on shares of Jazz Pharmaceuticals from $225.00 to $233.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. HC Wainwright lifted their target price on shares of Jazz Pharmaceuticals from $185.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, November 3rd. Royal Bank of Canada lifted their target price on shares of Jazz Pharmaceuticals from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. Jefferies Financial Group lifted their target price on shares of Jazz Pharmaceuticals from $151.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Finally, UBS Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 15th. They issued a “buy” rating and a $174.00 target price for the company.

NASDAQ JAZZ opened at $162.99 on Thursday. Jazz Pharmaceuticals has a 52-week low of $86.88 and a 52-week high of $166.98. The company has a 50-day simple moving average of $153.53 and a 200 day simple moving average of $137.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.84 and a current ratio of 3.98. The company has a market capitalization of $9.08 billion, a PE ratio of 51.42, a price-to-earnings-growth ratio of 5.81 and a beta of 1.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported $4.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.08 by $0.23. Jazz Pharmaceuticals had a net margin of 7.86% and a return on equity of 20.16%. The business had revenue of $600.90 million during the quarter, compared to the consensus estimate of $577.62 million. During the same quarter last year, the company posted $4.10 earnings per share. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, analysts forecast that Jazz Pharmaceuticals will post 10.91 EPS for the current fiscal year.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $145.13, for a total value of $145,130.00. Following the completion of the sale, the chief executive officer now owns 331,180 shares of the company’s stock, valued at approximately $48,064,153.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul L. Berns sold 4,691 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $150.42, for a total transaction of $705,620.22. Following the completion of the sale, the director now directly owns 14,431 shares of the company’s stock, valued at approximately $2,170,711.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,079 shares of company stock valued at $3,812,981. 4.60% of the stock is currently owned by company insiders.

Several institutional investors have recently made changes to their positions in JAZZ. BlackRock Inc. boosted its stake in shares of Jazz Pharmaceuticals by 53.7% in the 3rd quarter. BlackRock Inc. now owns 6,095,185 shares of the specialty pharmaceutical company’s stock valued at $869,111,000 after purchasing an additional 2,129,982 shares in the last quarter. State Street Corp lifted its stake in Jazz Pharmaceuticals by 44.3% in the 3rd quarter. State Street Corp now owns 2,160,823 shares of the specialty pharmaceutical company’s stock worth $308,112,000 after purchasing an additional 663,824 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in Jazz Pharmaceuticals by 61.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 808,725 shares of the specialty pharmaceutical company’s stock worth $115,316,000 after purchasing an additional 306,546 shares in the last quarter. LSV Asset Management lifted its stake in Jazz Pharmaceuticals by 9.7% in the 3rd quarter. LSV Asset Management now owns 2,440,957 shares of the specialty pharmaceutical company’s stock worth $348,056,000 after purchasing an additional 215,526 shares in the last quarter. Finally, Wedge Capital Management L L P NC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth $27,809,000. 93.93% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Further Reading: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.